Chimeric Therapeutics (CHM) EGM Presentation 2024 summary

Company overview

• Focuses on cancer cell therapy with three CAR-T and NK cell assets in four Phase 1/1b clinical trials.

• Operates under ASX: CHM, with a market cap of ~$10M and 841M shares on issue as of Dec 2024.

• Holds a robust and long-life patent portfolio, supporting its innovative therapies.

• Major shareholder is Paul Hopper with 11.1%.

Technology and clinical pipeline

• Portfolio includes CHM CDH17, CHM CLTX, and CHM CORE-NK, sourced from leading institutions like UPenn, City of Hope, and Case Western.

• Four clinical trials are open at top US centers, including Sarah Cannon, MD Anderson, and Case Western.

• CHM CDH17 is the first CDH17 CAR-T in clinical trials; CLTX-CAR is first-in-class for brain cancer.

• CAR-T therapy uses patient blood cells, engineered and infused back, with over a decade of global use.

Clinical results and milestones

• CHM CORE-NK showed ongoing complete response over 48 months in high-risk blood cancer, with no dose-limiting toxicities.

• Combination trial with CORE-NK and TGF-B also achieved complete response by day 28, with strong safety profile.

• 2023 achievements include FDA IND clearance, first patient dosed, and positive preliminary data in GBM.

• Multiple clinical updates and deliverables expected in the next 12 months.